 Jessica Christenson
Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 11 | 2024 | 188 | 2.520 |
Why?
| | Receptors, Androgen | 7 | 2023 | 143 | 1.650 |
Why?
| | Androgen Receptor Antagonists | 5 | 2021 | 36 | 1.410 |
Why?
| | Dopamine and cAMP-Regulated Phosphoprotein 32 | 2 | 2015 | 9 | 0.970 |
Why?
| | Breast Neoplasms | 6 | 2021 | 2139 | 0.680 |
Why?
| | Pulmonary Alveoli | 1 | 2022 | 366 | 0.670 |
Why?
| | Cell Cycle | 1 | 2021 | 581 | 0.590 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2017 | 66 | 0.540 |
Why?
| | Gonadal Steroid Hormones | 1 | 2018 | 132 | 0.530 |
Why?
| | Epithelial Cells | 1 | 2022 | 1036 | 0.520 |
Why?
| | Tryptophan | 3 | 2024 | 169 | 0.480 |
Why?
| | Receptor, ErbB-2 | 3 | 2016 | 336 | 0.470 |
Why?
| | Quinazolines | 1 | 2015 | 242 | 0.450 |
Why?
| | Mammary Glands, Animal | 1 | 2014 | 121 | 0.430 |
Why?
| | Lung Neoplasms | 2 | 2017 | 2323 | 0.410 |
Why?
| | Antineoplastic Agents | 3 | 2018 | 2058 | 0.340 |
Why?
| | Cell Line, Tumor | 9 | 2024 | 3160 | 0.280 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2021 | 1333 | 0.260 |
Why?
| | Tryptophan Oxygenase | 3 | 2024 | 33 | 0.250 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2024 | 52 | 0.230 |
Why?
| | Neoplasm Invasiveness | 1 | 2024 | 480 | 0.210 |
Why?
| | Kallikreins | 1 | 2021 | 29 | 0.190 |
Why?
| | Epithelium | 1 | 2022 | 306 | 0.190 |
Why?
| | Adipokines | 1 | 2021 | 46 | 0.190 |
Why?
| | Anoikis | 1 | 2021 | 32 | 0.180 |
Why?
| | Prostate-Specific Antigen | 1 | 2021 | 160 | 0.180 |
Why?
| | Membrane Transport Proteins | 1 | 2021 | 148 | 0.170 |
Why?
| | Mice, Transgenic | 2 | 2017 | 2069 | 0.170 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2021 | 155 | 0.170 |
Why?
| | Respiratory Mucosa | 1 | 2022 | 305 | 0.170 |
Why?
| | Estrogen Receptor alpha | 1 | 2020 | 134 | 0.160 |
Why?
| | Mice | 5 | 2021 | 16579 | 0.160 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2023 | 957 | 0.150 |
Why?
| | Animals | 7 | 2021 | 34501 | 0.150 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 387 | 0.140 |
Why?
| | Mammary Tumor Virus, Mouse | 1 | 2017 | 43 | 0.140 |
Why?
| | Dihydrotestosterone | 1 | 2017 | 39 | 0.140 |
Why?
| | Androgen Antagonists | 1 | 2017 | 78 | 0.130 |
Why?
| | Receptors, Estrogen | 2 | 2016 | 428 | 0.130 |
Why?
| | Ribonuclease III | 1 | 2016 | 37 | 0.130 |
Why?
| | Carcinogenesis | 1 | 2018 | 209 | 0.130 |
Why?
| | Antibody Specificity | 1 | 2016 | 182 | 0.130 |
Why?
| | Female | 12 | 2024 | 68127 | 0.130 |
Why?
| | DEAD-box RNA Helicases | 1 | 2016 | 64 | 0.120 |
Why?
| | Trastuzumab | 1 | 2015 | 100 | 0.120 |
Why?
| | Humans | 15 | 2024 | 128524 | 0.120 |
Why?
| | Antibodies | 1 | 2016 | 391 | 0.110 |
Why?
| | Gene Knockout Techniques | 1 | 2014 | 109 | 0.110 |
Why?
| | Biomarkers, Tumor | 2 | 2021 | 1182 | 0.110 |
Why?
| | Cell Nucleus | 1 | 2017 | 579 | 0.110 |
Why?
| | Cell Proliferation | 2 | 2021 | 2335 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 998 | 0.100 |
Why?
| | Neoplastic Stem Cells | 1 | 2017 | 384 | 0.100 |
Why?
| | Protein Isoforms | 1 | 2014 | 375 | 0.100 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 840 | 0.100 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1669 | 0.100 |
Why?
| | MicroRNAs | 1 | 2018 | 671 | 0.100 |
Why?
| | Disease Models, Animal | 1 | 2021 | 3943 | 0.090 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2015 | 749 | 0.090 |
Why?
| | Lung | 1 | 2022 | 3741 | 0.080 |
Why?
| | Disease Progression | 1 | 2017 | 2603 | 0.080 |
Why?
| | Cell Line | 1 | 2014 | 2731 | 0.080 |
Why?
| | Kynurenine | 2 | 2018 | 105 | 0.070 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 5257 | 0.060 |
Why?
| | Up-Regulation | 2 | 2017 | 826 | 0.050 |
Why?
| | Receptors, Progesterone | 2 | 2016 | 345 | 0.050 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 1 | 2023 | 32 | 0.050 |
Why?
| | Feedback, Physiological | 1 | 2021 | 74 | 0.040 |
Why?
| | Androgens | 1 | 2021 | 174 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 810 | 0.040 |
Why?
| | Phenylthiohydantoin | 1 | 2017 | 44 | 0.030 |
Why?
| | Mutation | 2 | 2020 | 3692 | 0.030 |
Why?
| | Heterografts | 1 | 2017 | 128 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2018 | 194 | 0.030 |
Why?
| | Nitriles | 1 | 2017 | 160 | 0.030 |
Why?
| | Benzamides | 1 | 2017 | 194 | 0.030 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 209 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 311 | 0.030 |
Why?
| | Paclitaxel | 1 | 2017 | 214 | 0.030 |
Why?
| | Gene Expression | 1 | 2020 | 1462 | 0.030 |
Why?
| | Mice, Nude | 1 | 2017 | 682 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2017 | 355 | 0.030 |
Why?
| | Hormones | 1 | 2015 | 140 | 0.030 |
Why?
| | Protein Transport | 1 | 2015 | 422 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2016 | 681 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2015 | 218 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 1936 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3023 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2015 | 10163 | 0.010 |
Why?
| | Young Adult | 1 | 2016 | 12320 | 0.010 |
Why?
| | Aged | 1 | 2016 | 21971 | 0.010 |
Why?
| | Male | 1 | 2021 | 62883 | 0.010 |
Why?
| | Middle Aged | 1 | 2016 | 30893 | 0.010 |
Why?
| | Adult | 1 | 2016 | 35315 | 0.010 |
Why?
|
|
Christenson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|